References
- Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15 (4): 573–81.
- Health Protection Agency, Summary points on C. difficile infection (CDI). London: HPA, 2012 (http://hpa.org.uk/webc/HPAwebFile/HPAweb_C/1278944283388).
- Wilcox MH. C. difficile infection: appendix. J Antimicrob Chemother 1998; 41 (Suppl C): 71–2.
- Inweregbu K, Dave J, Pittard A. Nosocomial infections. Contin Educ Anaesth Crit. Care Pain 2005; 5 (1): 14–7 (doi: 10.1093/bjaceaccp/mki006).
- Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired C. difficile infection. J Hosp Infect 1996; 34 (1): 23–30.
- Eastwood K, Else P Charlett A, Wilcox M. Comparison of nine commercially available C. difficile toxin detection assays, a realtime PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009; 47 (10): 3211–7.
- Robotham J, Wilcox M. Updated DH/ARHAI guidance on the diagnosis and reporting of C. difficile. London: DH, 2012 (www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_133016.pdf).
- Pepin J, Saheb N, Coulombe MA et al. Emergence of fluroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhoea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41 (9): 1254–60.
- Lowe DO, Mamdani M, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006; 43 (10): 1272–6.
- Teasly DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2 (8358): 1043–6.
- Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graininger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile associated diarrhea. Clin Infect Dis 1996; 22 (5): 813–8.